Moderna doses first participant in phase 3 trial of mRNA norovirus vaccine, mRNA-1403: Cambridge, Massachusetts Thursday, October 3, 2024, 12:00 Hrs [IST] Moderna, Inc, a global l ...
Some results have been hidden because they may be inaccessible to you